TECX Tectonic Therapeutic Inc.: Enterprise Value to EBITDA Ratio
The financial model of Tectonic Therapeutic, Inc. (TECX) relies on partnerships with industry behemoths and the monetization of drug-creation technologies through royalties. The company's operations are not subject to market cycles or seasonality, demonstrating resilience to external crises. However, a lack of profitability and high expenses make the business dependent on investments and GPCR antibody tests. This EV/EBITDA market price chart captured the metric at 0.00.
Comprehensive metric breakdowns and analytics for Tectonic (TECX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Tectonic Therapeutic, Inc.|TECX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Tectonic Therapeutic|TECX - Company Cumulative Indebtedness|Debts to Book Capitalization Tectonic Therapeutic, Inc.|TECX - Long-Term Debt|Company Short-Term Debts Tectonic Therapeutic|Quick Liquidity Indicator tectonictx.com
- financial results and valuation multiples details:
TECX - Profit After Payment of Taxes|Expected Profit Tectonic Therapeutic, Inc.|TECX - Market Cap to Earnings|Future Price to Earnings tectonictx.com|TECX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Tectonic|TECX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Tectonic Therapeutic|TECX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months tectonictx.com|TECX - Earnings per share increase in current year|Expected earnings per share growth for next year Tectonic Therapeutic, Inc.
- company sales and revenue statistics:
General company analysis:Tectonic TECX
For a Tectonic Therapeutic, Inc. (TECX) investor, it is critical to weigh market capitalization against actual asset management efficiency. This ratio correlates the total enterprise value, including debt obligations, with its operating profit before taxes, depreciation, and amortization. Analyzing the EV/EBITDA valuation metric for debt and operating leverage allows for the identification of company undervaluation relative to historical values. However, the absence of stable cash flow due to early-stage clinical trials renders this metric extremely volatile.
Competitor analysis
Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TNXP (Tonix Pharmaceuticals Holding Corp.)|EV/EBITDA Multiple SXT China (SXTC)|eupraxiapharma.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|invizyne.com - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ORMP (Oramed Pharmaceuticals Inc.)|ENTX: EV/EBITDA Multiple|MindWalk Holdings Inc. (HYFT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to Operating Income Before Depreciation CPIX (Cumberland Pharmaceuticals Inc.)|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Corporation|EV/EBITDA Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio
